St Jude

St. Jude Medical, Inc. has gained CE Mark approval and announced first use of the FlexAbility™ Ablation Catheter, a novel ablation technology used by electrophysiologists for the treatment of cardiac arrhythmias.

St. Jude Medical, Inc. has released sales and net earnings for the second quarter ended June 28, 2014, showing net sales up by 3% over the same period a year ago, at $1.448 billion.

St. Jude Medical, Inc. is to acquire privately held NeuroTherm, Inc., a manufacturer of interventional pain management therapies, for approximately $200 million in cash.

St. Jude Medical, Inc. has completed its acquisition of CardioMEMS, Inc., developer of the CardioMEMS™ HF System. The acquisition was completed on May 30, 2014.

Preliminary results from the St. Jude Medical EnligHTN III study suggest the company’s second-generation EnligHTN™ renal denervation system provides safe and effective therapy for patients with drug-resistant, uncontrolled hypertension six months post-procedure.

The big news in transcatheter aortic valve development is that St. Jude Medical, Inc. has seen the first patient implants in the Portico™ Re-sheathable Transcatheter Aortic Valve System U.S. IDE Trial (PORTICO trial). The trial is evaluating the Portico™ Transcatheter Aortic Valve System, claimed by St. Jude to be the first aortic heart valve that is repositionable until fully deployed.

In a new study, St.Jude’s Quadripolar left ventricular pacing system demonstrated 53% reduction in hospitalization translating into 62% overall cost reduction compared with its non-Quadripolar system.

St. Jude Medical, Inc., has announced results of the TOCCASTAR clinical trial, the first prospective, randomized study of contact-force ablation technology for the treatment of paroxysmal atrial fibrillation (AF). The trial met its primary endpoints and supplements the growing body of evidence that supports the safety and effectiveness of contact-force ablation technology.

St. Jude is sounding punchy, expecting revenue gains based on a flurry of new product approvals.

St. Jude Medical, Inc., is trumpeting the U.S. FDA approval of its Protégé™ IPG, the first and only neurostimulation system that allows spinal cord stimulation (SCS) technology upgrades to be made via software updates.

St. Jude Medical, Inc. has announced approval from the U.S. FDA for the Allure Quadra™ Cardiac Resynchronization Therapy Pacemaker (CRT-P), which provides additional pacing innovations for physicians to treat patients with heart failure. The company also announced FDA approvals for the Assurity™ pacemaker and Endurity™ pacemaker families of devices.

St. Jude Medical, Inc. has announced the global launch of the Optisure™ Defibrillation Lead, joining the Optim™ lead family, which includes the company’s now famous Durata™ Defibrillation Lead.

St. Jude Medical, Inc. has seen its Prodigy™ Chronic Pain System with Burst Technology gain CE Mark approval, which it says will be followed by European launch.

St. Jude Medical’s large European clinical trial of its Nanostim pacemaker is hoped to add to the building evidence supporting strong safety profile and performance of the world’s first leadless pacemaker.

St. Jude Medical, Inc. has announced the first U.S. implant in the company’s LEADLESS II pivotal trial designed to evaluate the Nanostim™ leadless pacemaker on its way to U.S. FDA approval.

St. Jude Medical, Inc. is trumpeting the first post-approval implant of the Nanostim™ leadless pacemaker in the U.K. The world’s first retrievable leadless pacemaker was implanted at St. Bartholomew’s Hospital in London, UK, by Professor Richard Schilling.